Citations

Showing 10 of 108152 citations.

Primary Prevention of Cardiovascular Disease
Jain, Atul , Jain, Atul, Davis, Andrew M.

Mayo Clinic

JAMA | October 4, 2019 | Volume: 322 | Issue: 18 | Pages: 1817

10.1001/jama.2019.15915 | PMID 31584604 Get It

Goal-Directed Achievement Through Geographic Location (GAGL) Reduces Patient Length of Stay and Adverse Events
Maniaci, Michael J. , Dawson, Nancy L. , Cowart, Jennifer B. , Richie, Eugene, Suryaprasad, Anil, Hodge, David O. , Joyce, Nicole , Kernan, Carol A., Stone, Laurie A., Burton, M. Caroline , Richie, Eugene M, Suryaprasad, Anil G, Joyce, Nicole E , Dawson, Nancy L , Maniaci, Michael J

Mayo Clinic

American Journal of Medical Quality | October 4, 2019 | Volume: 35 | Issue: 4 | Pages: 323-329

10.1177/1062860619879977 | PMID 31581786 Get It

This prospective cohort study aimed to improve hospital outcomes through geographic location of hospitalist patients and conducting daily multidisciplinary team rounds—Goal-directed Achievements through Geographic Location (GAGL). Patients were admitted to a geographic (GAGL) study unit where daily multidisciplinary rounds took place among nursing, case management, a hospitalist, pharmacy, physical and occupational therapy, respiratory therapy, and nutrition services. A total of 985 (56.4%) patients were admitted to the GAGL study unit and 760 patients (43.6%) were admitted to non-GAGL units. Patients admitted to the GAGL study unit had a shorter average length of stay (3.64 days vs 4.35 days, P = .0001) and a lower number of risk events (91 [9.2%] vs 93 [12.2%], P = .038). There was no significant difference in 30-day readmissions, avoidable day events, or code blue team activations. GAGL provides a framework for hospital organizations to improve provider communication, hospital efficiency, and patient safety.
Management of irritable bowel syndrome with diarrhea: a review of nonpharmacological and pharmacological interventions
Cangemi, David J. , Lacy, Brian E.

Mayo Clinic

Therapeutic Advances in Gastroenterology | October 4, 2019 | Volume: 12 | Issue: No issue available | Pages: No page available

10.1177/1756284819878950 | PMID 31632456 Get It

Irritable bowel syndrome (IBS) is a common gastrointestinal (GI) condition involving numerous potential causative factors (e.g. alterations in gut microbiota, motility, brain–gut axis). Several interventions are available for the management of patients with IBS, but no universal management algorithm currently exists. The aim of this article is to review interventions that may be considered in the management of patients with IBS with diarrhea (IBS-D). Nonpharmacological interventions include dietary and lifestyle modification, which are generally used as first-line therapy. Probiotics have demonstrated efficacy and safety in patients with IBS, but studies are inconsistent in strains examined, dosing, and treatment duration. Psychological therapies (e.g. cognitive behavioral therapy, hypnotherapy) also may improve IBS symptoms. Pharmacological interventions for the management of IBS-D include the US Food and Drug Administration–approved agents eluxadoline, rifaximin, and alosetron, as well as loperamide, smooth muscle antispasmodics, bile acid sequestrants, and antidepressants (i.e. tricyclic antidepressants, selective serotonin reuptake inhibitors). Eluxadoline and rifaximin have been shown to improve abdominal pain and stool consistency in patients with IBS-D. In addition, data indicate that alosetron improves IBS symptoms; however, it is approved only for women with severe IBS-D. Of the three approved agents, rifaximin has the most favorable safety profile. The risk–benefit ratio is an important consideration with every medication, but is especially important in the treatment of functional GI disorders such as IBS-D. Thus, the most troublesome symptoms, quality of life, symptom intensity, and individual patient preferences should be considered when formulating a management plan for patients with IBS-D.
Effectiveness of gastric electrical stimulation in gastroparesis: Results from a large prospectively collected database of national gastroparesis registries
Abell, Thomas L. , Yamada, Goro , McCallum, Richard W. , Natta, Mark L. Van , Tonascia, James , Koch, Kenneth L. , Sarosiek, Irene , Farrugia, Gianrico , Grover, Madhusudan , Snape, William J., Shulman, Robert J. , Hamilton, Frank A., Pasricha, Pankaj J. , Grover, Madhusudan , Hasler, W L , Nguyen, Linda A , Kuo, Braden , Shulman, Robert , Abell, T L , Parkman, Henry P. , Hasler, William L. , Nguyen, Linda Anh B. , Kuo, Braden

Mayo Clinic

Neurogastroenterology & Motility | October 4, 2019 | Volume: 31 | Issue: 12 | Pages: No page available

10.1111/nmo.13714 | PMID 31584238 Get It

Abstract Background Gastric electrical stimulation (GES) for treating gastroparesis symptoms is controversial. Methods We studied 319 idiopathic or diabetic gastroparesis symptom patients from the Gastroparesis Clinical Research Consortium (GpCRC) observational studies: 238 without GES and 81 with GES. We assessed the effects of GES using change in GCSI total score and nausea/vomiting subscales between baseline and 48 weeks. We used propensity score methods to control for imbalances in patient characteristics between comparison groups. Key Results GES patients were clinically worse (40% severe vs. 18% for non‐GES; P < .001); worse PAGI‐QOL (2.2. vs. 2.6; P = .003); and worse GCSI total scores (3.5 vs. 2.8; P < .001). We observed improvements in 48‐week GCSI total scores for GES vs. non‐GES: improvement by ≥ 1‐point (RR = 1.63; 95% CI = (1.14, 2.33); P = .01) and change from enrollment (difference = −0.5 (−0.8, −0.3); P < .001). When adjusting for patient characteristics, symptom scores were smaller and not statistically significant: improvement by ≥ 1‐point (RR = 1.29 (0.88, 1.90); P = .20) and change from the enrollment (difference = −0.3 (−0.6, 0.0); P = .07). Of the individual items, the nausea improved by ≥ 1 point (RR = 1.31 (1.03, 1.67); P = .04). Patients with GCSI score ≥ 3.0 tended to improve more than those with score < 3.0. (Adjusted P = 0.02). Conclusions and Inferences This multicenter study of gastroparesis patients found significant improvements in gastroparesis symptoms among GES patients. Accounting for imbalances in patient characteristics, only nausea remained significant. Patients with greater symptoms at baseline improved more after GES. A much larger sample of patients is needed to fully evaluate symptomatic responses and to identify patients likely to respond to GES.
Nomenclature of Genetically Determined Myoclonus Syndromes: Recommendations of the International Parkinson and Movement Disorder Society Task Force
Veen, Sterre van der , Zutt, Rodi, Klein, Christine , Berkovic, Samuel F. , Caviness, John N., Shibasaki, Hiroshi, Koning, Tom J. de , Tijssen, Marina A.J. , Tijssen, Marina A J , Klein, Christine , Marras, Connie

Mayo Clinic

Movement Disorders | October 4, 2019 | Volume: 34 | Issue: 11 | Pages: 1602-1613

10.1002/mds.27828 | PMID 31584223 Get It

AbstractGenetically determined myoclonus disorders are a result of a large number of genes. They have wide clinical variation and no systematic nomenclature. With next‐generation sequencing, genetic diagnostics require stringent criteria to associate genes and phenotype. To improve (future) classification and recognition of genetically determined movement disorders, the Movement Disorder Society Task Force for Nomenclature of Genetic Movement Disorders (2012) advocates and renews the naming system of locus symbols. Here, we propose a nomenclature for myoclonus syndromes and related disorders with myoclonic jerks (hyperekplexia and myoclonic epileptic encephalopathies) to guide clinicians in their diagnostic approach to patients with these disorders. Sixty‐seven genes were included in the nomenclature. They were divided into 3 subgroups: prominent myoclonus syndromes, 35 genes; prominent myoclonus syndromes combined with another prominent movement disorder, 9 genes; disorders that present usually with other phenotypes but can manifest as a prominent myoclonus syndrome, 23 genes. An additional movement disorder is seen in nearly all myoclonus syndromes: ataxia (n = 41), ataxia and dystonia (n = 6), and dystonia (n = 5). However, no additional movement disorders were seen in related disorders. Cognitive decline and epilepsy are present in the vast majority. The anatomical origin of myoclonus is known in 64% of genetic disorders: cortical (n = 34), noncortical areas (n = 8), and both (n = 1). Cortical myoclonus is commonly seen in association with ataxia, and noncortical myoclonus is often seen with myoclonus‐dystonia. This new nomenclature of myoclonus will guide diagnostic testing and phenotype classification. © 2019 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.
Cover Picture: Biotechnology Journal 10/2019
Duchamp, Margaux , Liu, Tingting , Kappings, Vanessa, Öklü, Rahmi , Oklu, Rahmi , Genderen, Anne Metje van , Ellisen, Leif W. , Zhang, Yu Shrike

Mayo Clinic

Biotechnology Journal | October 4, 2019 | Volume: 14 | Issue: 10 | Pages: No page available

10.1002/biot.201970101 Get It

Engineered nanoparticles for systemic siRNA delivery to malignant brain tumours
Karlsson, Johan , Rui, Yuan , Kozielski, Kristen , Placone, Amanda L., Choi, Olivia, Tzeng, Stephany Y. , Keyes, Jamal J., Bogorad, Max I. , Guerrero‐Cazares, Hugo , Quiñones‐Hinojosa, Alfredo , Green, Jordan J. , Guerrero-Cázares, Hugo, Searson, Peter C , Green, Jordan J , Guerrero-Cazares, Hugo , Tzeng, Stephany Y , Choi, Olivia, Kim, Jayoung , Gabrielson, Kathleen L.

Mayo Clinic

Nanoscale | October 3, 2019 | Volume: 11 | Issue: 42 | Pages: 20045-20057

10.1039/c9nr04795f | PMID 31612183 Get It

Bioreducible nanoparticles were engineered for safe and effective systemic siRNA delivery, including crossing the blood–brain barrier to achieve in vivo gene silencing in an orthotopic glioblastoma mouse model.
The importance of teaching clinical anatomy in surgical skills education: Spare the patient, use a sim!
Clifton, William , Damon, Aaron , Nottmeier, Eric W. , Pichelmann, Mark A., Nottmeier, Eric, Pichelmann, Mark, Clifton, William E

Mayo Clinic

Clinical Anatomy | October 3, 2019 | Volume: 33 | Issue: 1 | Pages: 124-127

10.1002/ca.23485 | PMID 31581311 Get It

Anatomical knowledge is a key tenet in graduate medical and surgical education. Classically, these principles are taught in the operating room during live surgical experience. This puts both the learner and the patient at a disadvantage due to environment, time, and safety constraints. Educational adjuncts such as cadaveric courses and surgical skills didactics have been shown to improve resident confidence and proficiency in both anatomical knowledge and surgical techniques. However, the cost‐effectiveness of these courses is a limiting factor and in many cases prevents implementation within institutional training programs. Anatomical simulation in the form of “desktop” three‐dimensional (3D) printing provides a cost‐effective adjunct while maintaining educational value. This article describes the anatomical and patient‐centered approach that led to the establishment of our institution's 3D printing laboratory for anatomical and procedural education. Clin. Anat. 32:124–127, 2019. © 2019 Wiley Periodicals, Inc.
The Impact of Frailty on Technique Failure and Mortality in Patients on Home Dialysis
Brar, Ranveer , Whitlock, Reid , Komenda, Paul , Lerner, Blake, Bohm, Clara , Thorsteinsdottir, Bjoerg , Rigatto, Claudio , Tangri, Navdeep , Prasad, Bhanu , Thorsteinsdottir, Bjorg

Mayo Clinic

Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis | October 3, 2019 | Volume: 39 | Issue: 6 | Pages: 532-538

10.3747/pdi.2018.00195 | PMID 31582467 Get It

Background Patients on home dialysis therapies experience technique failure, which is associated with morbidity and mortality. Reasons for technique failure are complex, and often related to functional decline in the patient or caregiver. Frailty is associated with an increased risk of adverse health outcomes. We investigated the impact of frailty on technique failure and mortality in a prospective cohort of patients on home dialysis therapies. Methods We collected objective (Fried criteria and Short Physical Performance Battery [SPPB]), and subjective (physician and nurse impression) measures of frailty from 109 prevalent home dialysis patients. Our primary outcome was a composite of technique failure, defined as a permanent unplanned transition (> 30 days in duration) to facility-based hemodialysis or all-cause death. The association between different frailty assessment tools and the primary composite outcome was evaluated using Cox models. Results Fried criteria and physician impression was associated with a greater than 2-fold increase in risk of our composite outcome (HR: 2.10 [95% CI 1.09 – 3.99], 2.15 [95% CI 1.15 – 4.00, respectively] in adjusted analyses. Weakness and weight loss subdomains of the Fried criteria were both associated with an increased risk of our composite outcome in adjusted analyses (HR: 2.16 [95% CI 1.23 – 3.78], 2.69 [95% CI 1.39 – 5.40], respectively). Conclusions Objective and subjective measures of frailty are associated with a more than 2-fold higher risk of technique failure or death in patients undergoing home dialysis. Assessing frailty as part of the clinical evaluation for home dialysis therapies may be useful for prognostication and clinical management.
Unusual Presentation of Recurrent Gallstone Ileus: A Case Report and Literature Review
Osagiede, Osayande , Pacurari, Paula, Jrebi, Nezar , Colibaseanu, Dorin , Jrebi, Nezar , Osagiede, Osayande

Mayo Clinic

Case Reports in Gastrointestinal Medicine | October 3, 2019 | Volume: 2019 | Issue: No issue available | Pages: 1-4

10.1155/2019/8907068 | PMID 31687227 Get It

Background. Gallstone ileus (GSI) is a rare form of small bowel obstruction (SBO) in patients with cholelithiasis, which is often poorly managed. Enhanced abdominal computed tomography (CT) with contrast is considered the most helpful diagnostic tool, as it is highly sensitive, specific, and accurate. We report an interesting case of recurrent GSI that was not detected by CT but diagnosed intraoperatively. Case Presentation. A 49-year-old female with a previous history of choledocholithiasis and ERCP presented to the emergency department following episodes of sudden cramping, epigastric pain, and nausea. An abdominal CT revealed evidence of SBO with clear evidence of GSI and a cholecystoduodenal fistula. Laparoscopic exploration of the small bowel revealed a large, calcified 3.5 cm × 3 cm gallstone with evidence of pressure necrosis; segmental bowel resection with stapled anastomosis was performed and patient recovered appropriately after surgery. Cholecystectomy was not performed due to multiple co-morbidities and absence of gallbladder stones. However, she presented two months later with signs and symptoms of SBO. A repeat abdominal CT showed dilated bowel with no clear transition point. This was suspected to be due to adhesions. After an initial conservative treatment which produced mild improvement, laparotomy was performed which revealed a second large non-calcified gallstone and necrotic small bowel with a pocket of abscess. Conclusion. The most sensitive diagnostic tool for GSI is enhanced abdominal CT but dilemma arises when GSI is not detected on CT. A high index of suspicion and further exploration are required in order not to miss other vital findings.